'A confused scientist'

International Symposium on Neuropsychiatry and HIV

Dr Brendan Payne, BMBS PhD FRCPath

Honorary Consultant, Infectious Diseases & Virology

Newcastle University / Newcastle-upon-Tyne Hospitals, UK

Case history: Background

- 'M', 46F
- Born in Nigeria, in UK since 2001
- PhD (2006), works as Biomedical Scientist

HIV history

- Diagnosed HIV+ 2012: collapse, pneumonia, ITU stay
- Severe microcytic anaemia, likely due to uterine fibroids
- Baseline bloods:
 - CD4 T-cell count 35 cells/µL
 - HIV viral load 200,000 copies/mL
- Possible undisclosed prior HIV diagnosis in Nigeria?
- Baseline HIV viral resistance: nevirapine (V108I)
- Commenced ART: TDF/FTC/DRV/r

HIV treatment response



Neuropsychiatric history

- At HIV diagnosis (2012, aged 40): confused
 - Feeling 'frightened', 'trapped'
- (non-contrast) MRI brain mild atrophy only
- CSF: protein 0.61 g/L, glucose 3.1/5.5 , 0 WBC
- No pathogens identified:
 - CSF PCRs: toxoplasma / JC / HSV1&2, VZ, CMV neg
 - Treponemal Ab neg (blood), CrAg neg (blood / CSF)

Neuropsychiatric progress

- Initial confusion appeared to resolve with treatment of HIV and pneumonia
- Followed up by specialist HIV psychology service (2012):
 - Reported previous consultations with GP for depression (no current antidepressant medication)
 - Reports 'hearing voices' during childhood / adolescence, but these were always pleasant and/or 'fortune-telling' in nature
 - No prior diagnosis of psychosis
- Voices became more persecutory
 - Referred to community psychiatric service
- 2013: 'no psychiatric issues', 'not on medication', back at work'

Neuropsychiatric progress

- 2014-2016: no contact with mental health services
- 1/2017-5/2017 (aged 44): detained under MHA
 - Acute psychotic episode: diagnosed paranoid schizophrenia
 - paranoid persecutory beliefs
 - 3rd person hallucinations
 - elementary hallucinations (knocking)
 - Confused at initial presentation; MMSE 26/30 (2/2017)
 - Normal EEG
 - no MRI or CSF examination performed as felt to be low risk for HIV encephalitis
- Rx: aripiprazole, procycline

Neuropsychiatric progress

- 8/2017: 'no psychotic features'; aripiprazole switched to quetiapine (EPSE)
- 10/2017: reports not taking quetiapine
 - 'a little disorientated'
 - Planning to move away from area, therefore discharged back to GP
- 5/2018 (HIV clinic): 'tearful', 'odd affect'
 - Admits occasional missed doses of ART (always claimed 100% adherence previously)

Current episode

- 8/2018: detained again under MHA
 - Agitated, easily distressed, delusional
 - Home squalid, in state of disrepair
- Noted to have poor level of functioning, needing prompting for ADLs
- No focal neurological signs (has EPSE)
- Rx: flupenthixol

Neurocognitive testing (11/2018)

Test	Percentile (Score)	Range					
Test of Premorbid Functioning (TOPF)		Average					
Wechsler Adult Intelligence Scale- IV (WAIS-IV)							
 Verbal comprehension index overall Similarities Vocabulary 	9 th 37 th	Low Average Average					
Perceptual Reasoning index overall Block Design Matrix Reasoning 	16 th 1 st	Low Average Impaired					
Working Memory index overall Digit Span	5 th	Borderline					
Processing speed index overall Oding	1st	Impaired					
BIRT Memory and Infor	mation Processing Batter	ry (BMIPB)					
Story recall (verbal memory) Immediate Delayed Retained 	<2 nd <2 nd <2 nd	Impaired Impaired Impaired					
Figure recall (visual memory) Immediate Delayed Retained 	2 nd 10-25 th 10-25 th	Impaired Low Average Low Average					
List Learning Total A1-A5 Post distraction Distraction Total word recognition Total list recognition 	<2 nd 5 th 5 th <2 nd 2 nd	Impaired Borderline Borderline Impaired Impaired					
Delis-Kaplan Execu	tive Function System (D	KEFS)					
Verbal fluency Letter fluency Category fluency Category switching responses Category switching accuracy 	2 nd 0.1 st 0.1 st 0.1 st	Borderline Impaired Impaired Impaired Impaired					
Behavioural Assessment of Dysexecutive Syndrome (BADS)							
Key Search		Impaired					
 Version 1 Version 2 		Impaired Impaired					

12/2018



5/2012



ID and Neurology consults (12/2018)

CSF (12/12/2018)

- Prot 1.68 g/L
- 0 WBC
- PCRs neg: JC, HSV, VZ, enterovirus, CMV
- CSF CrAg neg
- Serum treponemal Ab neg
- HIV-1 RNA: 3840 c/mL

CSF (12/12/2018)

HIV-1 RNA: 3870 c/mL (plasma = 281)

ART class	5/2012	1/2013	12/2018
NRTI	TDF/FTC	TDF	ABC/3TC/AZT
NNRTI			
PI	DRV/r	DRV/r	DRV/r (bd)
INSTI		RAL	DTG

CSF (12/12/2018)

- Viral resistance: raltegravir (Y143C/R), nevirapine (V108I)
- CSF viral tropism failed to amplify
- Plasma VR failed to amplify

Date	protein	WBC	HIV-1 RNA
12/12/2018	1.68 g/L	0	3840 c/mL
15/1/2019	0.99 g/L	14 c/mm ³	<20 c/mL
10/4/2019	0.43 g/L	0	<20 c/mL



CSF (12/12/2019)

- Prot 1.68 g/L
- 0 WBC
- PCRs neg: JC, HSV, VZ, enterovirus, CMV, (low-level EBV)
- CSF CrAg neg
- Serum treponemal Ab neg
- HIV-1 RNA: 3840 c/mL
- Anti-NMDAR Ab positive (serum/CSF, fixed/live cell assays)

Clinical progress

- Currently in psychiatric rehabilitation unit
- Acute psychotic features resolved
 - Off anti-psychotic since 24/4/2019 ('thinking clearer since stopping')
- Still concern re. neurocognitive impairment formal retest pending
- ADLs improving, but some weeks / months away from discharge



HIV CNS viral escape

- Typical risk factors:
 - Previous VR
 - LLV
 - Suboptimal adherence
- Typical neuroimaging
- Typical CSF findings, VR
- Plausible clinical features (trouble with ADLs, reduced cognition)

- Definite CNS escape
- CSF escape definition (EACS):
 - either CSF HIV-VL detectable and plasma HIV-VL undetectable
 - or both CSF HIV-VL and plasma HIV-VL detectable, with CSF HIV-VL higher than plasma HIV-VL.
- Very likely symptomatic

Paranoid schizophrenia

- Fulfilled diagnostic criteria (DSM-5)
- Prior history of auditory hallucinations (specificity?)
- Responded to anti-psychotic medication
- Lack of other neurological findings

- Presence of confusion at each presentation (2012, 2017, 2018)
- Risk group for organic pathology

- Meets diagnostic criteria
- Organic element?

Anti-NMDAR encephalitis

- Presence of anti-NMDAR Ab (blood / CSF, live / fixed cell assays)
- Association of anti-NMDAR Ab and psychosis
- Association of anti-NMDAR Ab and CNS infections

- No other neurological features typical of autoimmune encephalitis
- Response to anti-psychotic medication without immunotherapy

Incidental finding?Causal / contributory?

Anti-NMDAR encephalitis

Commonest autoimmune encephalitis associated with neuronal cell surface antibodies

Classically affects young women, but can affect any age

Often paraneoplastic (esp. ovarian teratoma)

Some cases likely triggered by infection (usually 'viral' prodrome, association with herpes simplex encephalitis)

Anti-NMDAR encephalitis

Groups of symptoms

- 1 Psychiatric / behavioural (~80%, with ~60% as initial symptom)
- 2 Seizures (~70%)
- 3 Movement disorders (e.g. dyskinesias)
- 4 Memory loss
- 5 Speech disorder (reduced output, echolalia, perseveration etc., ~70%)
- 6 Reduced consciousness (>80% in first 3 weeks)
- 7 Autonomic dysfunction (~70%)
- 8 Central hypoventilation (~70%, may require ICU)

Anti-NMDAR encephalitis

CSF typically: pleocytosis, mild increased protein, oligoclonal bands

MRI: may be normal in >50%; increased signals on T2 and FLAIR, commonly cortical and subcortical and hippocampus.

EEG: abnormal in 90%

Anti-NMDAR Ab testing (Oxford Diagnostic Immunology Service):Fixed cell assay: 99% NPV, 100% PPVLive cell assay: 100% NPV, 50% PPV

'Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis'

	Titres	Patients with first-episode psychosis (n=228)	Controls (n=105)	Odds ratio (95% CI)	Adjusted odds ratio* (95% CI)
NMDAR antibodies	1:30-1:150	7 (3%)	0	5·4 (p=0·0204)†	
LGI1 antibodies	1:20-1:100	3 (1%)	0	2·3 (p=0·1298)†	
CASPR2 antibodies	1:100-1:250	2 (1%)	3 (3%)	0.3 (0.1–1.8)	2.2 (0.3–17.1)
GABA _A R antibodies	1:50-1:100	8 (4%)	1 (1%)	3.8 (0.5–30.7)	0.4 (0.3–3.6)
AMPAR antibodies		0	0		
Any neuronal cell surface antibody		20 (9%)	4 (4%)	2.4 (0.8–7.3)	0.5 (0.1–1.7)
Other antibodies					
VGKC-complex antibodies >150 pM‡		11 (5%)	3 (3%)	1.7 (0.5–6.3)	0.8 (0.2–3.2)
Antinuclear antibodies >1/160		7 (3%)	9 (9%)	0.5 (0.2–1.4)	3.6 (1.0–13.6)

Not replicated in all studies

Lennox et al. Lancet Psychiatry 2017

Psychosis of dual origin in HIV infection

Viral escape syndrome and autoimmune encephalitis

David Anguizola-Tamayo, MD, Jone Bocos-Portillo, MD, Lara Pardina-Vilella, MD, Aida Rodriguez-Sainz, MD, Iñigo Vicente-Olabarria, MD, Eduardo Martínez, MD, Marian Gomez-Beldarrain, MD, and Juan Carlos Garcia-Monco, MD

Neurology: Clinical Practice April 2019 vol. 9 no. 2 178-180 doi:10.1212/CPJ.00000000000582

Small number of case reports of anti-NMDAR Ab in HIV.

Most reported features of autoimmune encephalitis, but I found 2 reports in newonset psychosis.

Correspondence Dr. Garcia-Monco hospit05@sarenet.es





For discussion:

Can psychotic symptoms be a prominent feature of HIVE?

Can anti-NMDAR Ab ever be considered as an 'incidental' finding?

Could the acute psychosis be anti-NMDAR Ab driven, and if so, should this be treated with immunotherapy?

Can HIV CNS escape trigger the production of anti-NMDAR Ab, and if so, what is the clinical significance? Any suggestions very welcome!

Brendan.Payne@ncl.ac.uk

Thank you

Acknowledgements: Newcastle ID (Uli Schwab) Newcastle Neurology (Yi Ng) NTW Mental Health Services (Andrew Byrne, Bruce Owen)